Clinical Trials
26 trialsImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Rutgers, The State University of New Jersey
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Masonic Cancer Center, University of Minnesota
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
Masonic Cancer Center, University of Minnesota
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Biological Therapy in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
Roger Williams Medical Center
Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung
National Cancer Institute (NCI)
Biological Therapy in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer
National Cancer Institute (NCI)
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Cancer Research UK
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University